David J Mauro, Age 6020 Majestic Dr, East Freehold, NJ 07728

David Mauro Phones & Addresses

20 Majestic Dr, Freehold, NJ 07728

48 Poplar Pl, Freehold, NJ 07728

Scottsdale, AZ

Washington Crossing, PA

12 Battleground Rd, Perrineville, NJ 08535

26 Battleground Rd, Perrineville, NJ 08535

Millstone Township, NJ

Tinton Falls, NJ

Buck, PA

Keyport, NJ

Show more

Work

Position: Craftsman/Blue Collar

Education

Degree: Graduate or professional degree

Mentions for David J Mauro

Career records & work history

Medicine Doctors

David Mauro Photo 1

David M Mauro

David Mauro Photo 2

David John Mauro

Specialties:
Internal Medicine
Pathology
Anatomic Pathology & Clinical Pathology
Education:
Temple University Physicians (1996)

David Mauro resumes & CV records

Resumes

David Mauro Photo 37

David Mauro

David Mauro Photo 38

David Di Mauro

David Mauro Photo 39

Universidad Nacional Hermilio Valdizã N

Work:

Universidad Nacional Hermilio Valdizã N
David Mauro Photo 40

David Mauro

David Mauro Photo 41

David Mauro

David Mauro Photo 42

David Mauro

David Mauro Photo 43

David Mauro

Location:
United States
David Mauro Photo 44

David Mauro - Deer Park, NY

Work:
NYSE Euronext 2012 to 2000
Configuration Management - Lead Analyst
NYSE Euronext - New York, NY 2010 to 2012
Advanced Analytics - Lead Analyst
NYSE Euronext - Brooklyn, NY 2007 to 2010
Network Operations - Lead Analyst
SECURITIES INDUSTRY AUTOMATION CORPORATION - New York, NY 1988 to 2007
Network Operations - Analyst
SECURITIES INDUSTRY AUTOMATION CORPORATION - New York, NY 1986 to 1988 SECURITIES INDUSTRY AUTOMATION CORPORATION - New York, NY 1985 to 1986
Trading Floor Support Technician
Education:
Grumman Data Institute - Westbury, NY 2004
Certificate

Publications & IP owners

Us Patents

Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer

US Patent:
2022032, Oct 13, 2022
Filed:
Apr 20, 2022
Appl. No.:
17/725240
Inventors:
- New York NY, US
- Rahway NJ, US
Rodolfo Fleury Perini - Philadelphia PA, US
David J. Mauro - North Wales PA, US
Assignee:
PFIZER INC. - New York NY
MERCK SHARP & DOHME CORP. - Rahway NJ
International Classification:
C07K 16/28
A61K 39/395
A61K 31/4439
A61K 45/06
C07K 16/30
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.

Compositions And Methods For Tumor Immunotherapy

US Patent:
2021003, Feb 4, 2021
Filed:
Feb 12, 2019
Appl. No.:
16/969076
Inventors:
- Cambridge MA, US
- Iowa City IA, US
David Mauro - Washington Crossing PA, US
George Weiner - Iowa City IA, US
Mohammed Milhem - Iowa City IA, US
International Classification:
A61K 31/7125
C07K 16/28
Abstract:
Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer

US Patent:
2020032, Oct 15, 2020
Filed:
Jan 14, 2020
Appl. No.:
16/742657
Inventors:
- NEW YORK NY, US
- RAHWAY NJ, US
Rodolfo Fleury Perini - Philadelphia PA, US
David J. Mauro - North Wales PA, US
Assignee:
PFIZER INC. - NEW YORK NY
MERCK SHARPE & DOHME CORP. - RAHWAY NJ
International Classification:
C07K 16/28
A61K 39/395
A61K 31/4439
A61K 45/06
C07K 16/30
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L 1.

Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer

US Patent:
2017016, Jun 15, 2017
Filed:
Feb 3, 2015
Appl. No.:
15/115730
Inventors:
- New York NY, US
- Rahway NJ, US
Rodolfo Fleury Perini - Philadelphia PA, US
David J. Mauro - North Wales PA, US
International Classification:
C07K 16/28
C07K 16/30
A61K 39/395
A61K 31/4439
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.